Research Keyword: hallucinogenic compounds

Psilocybin for clinical indications: A scoping review

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Read More »

Psychedelic Psilocybin-Assisted Therapy Reduces Depressive Symptoms in Adults with Cancer and Depression

Researchers conducted a trial testing psilocybin-assisted therapy in cancer patients with depression. Participants received a single dose of psilocybin combined with therapy sessions. After eight weeks, most patients showed significant improvement in depression symptoms, with many achieving full remission. The treatment was generally safe with only mild side effects, and patients reported feeling more hopeful and better equipped to cope with their cancer diagnosis.

Read More »

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity

Scientists discovered that distantly related hallucinogenic mushrooms produce psilocybin, the psychoactive compound in magic mushrooms, through a shared set of genes that were likely transferred between species living in similar environments like dung and decaying wood. By sequencing the genomes of three different hallucinogenic mushroom species, researchers found nearly identical gene clusters responsible for making psilocybin, and evidence showing these genes jumped between unrelated fungal lineages. This discovery suggests that fungi in dung and wood environments may be rich sources of other bioactive compounds with potential medical applications.

Read More »

Current situation regarding psychedelics and magic mushroom in Korea

This article reviews the current status of psychedelic mushrooms and their potential medical uses in Korea. Several wild mushroom species containing psilocybin have been identified in Korea and can cause hallucinations and other nervous system effects lasting a few hours. While psychedelics show promise for treating depression and anxiety, Korea currently classifies them as controlled substances, and only approved clinical trials can be conducted with government permission.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

This study compared the chemical makeup of psilocybin mushroom mycelium (the root-like growth) versus fruiting bodies (the mushrooms themselves) to understand their different therapeutic potential. While fruiting bodies contain much higher levels of psilocybin, the psychoactive compound, mycelium accumulates other beneficial compounds like α-GPC that may enhance cognition and motor function without strong psychedelic effects. This research suggests that mushroom mycelium could be developed as a non-intoxicating therapeutic alternative with its own unique health benefits.

Read More »
Scroll to Top